Hub : Traits :

Mean time to correctly identify matches

312 significantly associated models · 76 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	96492298	97978299	1	1	2.2e-07	3.3e-06	1.5e-02	72	PTBP2
2	1	204982713	206329620	5	1	3.2e-11	6.7e-10	3.4e-01	98	PM20D1
3	2	23729232	25278723	2	1	5.7e-08	2.6e-08	1.0e+00	100	AC009228.1
4	2	200473658	202044716	1	1	7.3e-09	9.4e-10	1.4e-02	84	SPATS2L
5	3	46365783	48077701	2	1	2.2e-07	8.1e-08	2.6e-02	83	SETD2
6	5	111499732	112950045	6	1	1.2e-10	2.0e-10	8.9e-02	93	REEP5
7	5	138933151	140423473	2	1	4.4e-11	2.0e-11	1.1e-01	94	PFDN1
8	6	97341715	97979053	1	1	1.0e-07	9.8e-06	2.4e-03	53	C6orf167
9	6	108183628	109704062	1	1	4.2e-09	4.4e-11	2.6e-03	79	FOXO3
10	7	44090853	45498400	1	1	1.1e-07	1.4e-08	1.2e-02	80	ZMIZ2
11	7	122978928	124733550	1	1	3.8e-08	3.7e-09	2.4e-04	61	RP5-921G16.1
12	9	85899677	87315117	2	1	8.8e-12	6.7e-11	4.8e-01	99	RMI1
13	10	12239118	13839729	1	1	4.0e-08	1.1e-04	1.2e-01	84	CCDC3
14	10	14555086	16102103	1	1	1.3e-07	2.1e-07	1.0e-01	90	FAM171A1
15	11	30764890	32226445	1	1	1.4e-07	4.3e-06	7.7e-06	5	IMMP1L
16	11	45258966	48285906	14	1	4.6e-13	2.7e-11	3.2e-02	90	ARHGAP1
17	11	63295034	64687797	1	1	1.8e-07	5.4e-07	1.0e+00	100	TRPT1
18	12	48605088	50199949	6	1	5.2e-12	4.2e-13	4.3e-03	84	CCDC65
19	12	111154626	113517494	12	1	3.2e-12	2.1e-11	6.5e-02	92	SH2B3
20	17	6907070	7410212	1	1	2.7e-07	1.6e-07	9.9e-08	-3	C17orf81
21	17	43871147	45510971	8	2	3.0e-24	1.2e-19	8.5e-01	100	ARL17A KANSL1
22	17	75309351	76804316	2	1	1.3e-08	1.5e-07	8.4e-01	100	AC021593.1
23	18	33665455	35103667	1	1	7.6e-08	3.9e-10	7.0e-04	71	TPGS2
24	19	3309021	4735663	1	1	8.0e-08	1.8e-10	1.6e-04	65	PIAS4
25	20	46840115	48410403	2	1	4.7e-08	3.8e-07	2.0e-01	94	ARFGEF2

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Reaction Time	18.68	26	18	40.0	1.00	4.4e-27	AC009228.1 AC021593.1 ARFGEF2 ARHGAP1 ARL17A C17orf81 C6orf167 CCDC3 CCDC65 FAM171A1 FOXO3 IMMP1L KANSL1 PFDN1 PIAS4 PM20D1 PTBP2 REEP5 RMI1 RP5-921G16.1 SETD2 SH2B3 SPATS2L TPGS2 TRPT1 ZMIZ2
Blood Eosinophil Count	7.62	3	2	4.4	0.00	1.0e+00	C17orf81 RMI1 SH2B3
Hypothyroidism (self reported)	5.31	1	1	2.2	0.00	1.0e+00	SH2B3
Blood White Count	4.85	6	4	8.9	0.75	8.4e-02	AC009228.1 C6orf167 PIAS4 RMI1 SETD2 SH2B3
Medication: Levothyroxine sodium	4.70	1	1	2.2	0.00	1.0e+00	SH2B3
Hypothyroidism/myxoedema (self-reported)	4.53	1	1	2.2	0.00	1.0e+00	SH2B3
Birth weight	4.48	2	2	4.4	0.00	1.0e+00	C17orf81 SH2B3
Intelligence (Savage-Jansen 2018)	4.22	8	4	8.9	0.25	5.5e-01	ARFGEF2 ARHGAP1 ARL17A CCDC65 FOXO3 PFDN1 PIAS4 RMI1
Verbal and Numeric Reasoning (VNR)	4.05	5	3	6.7	0.36	5.6e-01	ARFGEF2 ARHGAP1 CCDC65 FOXO3 PFDN1
Systolic Blood Pressure	3.61	6	3	6.7	0.51	3.0e-01	ARFGEF2 ARL17A C17orf81 FOXO3 SH2B3 SPATS2L
Diastolic blood pressure, automated reading	3.41	2	1	2.2	0.00	1.0e+00	C17orf81 SH2B3
Birth weight of first child	3.13	3	1	2.2	0.00	1.0e+00	ARFGEF2 C17orf81 SH2B3
Peak expiratory flow (PEF)	2.99	2	1	2.2	0.00	1.0e+00	FOXO3 PM20D1
Qualifications: None of the above	2.93	4	0	0.0	0.56	4.4e-01	ARFGEF2 C6orf167 FOXO3 SPATS2L
Bipolar Disorder (2011)	2.86	1	0	0.0	0.00	1.0e+00	CCDC65
Loneliness, isolation	2.85	2	1	2.2	0.00	1.0e+00	ARFGEF2 SH2B3
Qualifications: O levels/GCSEs or equivalent	2.81	4	0	0.0	-0.25	7.5e-01	ARFGEF2 C6orf167 PIAS4 RMI1
Illnesses of father: None of the above (group 1)	2.79	3	0	0.0	0.00	1.0e+00	PIAS4 PM20D1 SH2B3
Impedance of arm (right)	2.77	9	4	8.9	0.06	8.7e-01	ARL17A CCDC65 FOXO3 IMMP1L PFDN1 PM20D1 REEP5 RMI1 SH2B3
Cardiovascular Disease	2.76	3	1	2.2	0.00	1.0e+00	C17orf81 C6orf167 SH2B3
Fluid intelligence score	2.76	4	1	2.2	0.23	7.7e-01	ARFGEF2 ARHGAP1 FOXO3 PFDN1
Vascular/heart problems diagnosed by doctor	2.71	3	1	2.2	0.00	1.0e+00	C17orf81 PIAS4 SH2B3
Blood Red Count	2.68	7	4	8.9	0.05	9.1e-01	AC009228.1 ARFGEF2 ARL17A IMMP1L PIAS4 SH2B3 SPATS2L
High blood pressure	2.64	3	1	2.2	0.00	1.0e+00	C17orf81 PIAS4 SH2B3
Arm fat mass (right)	2.64	9	3	6.7	-0.42	2.6e-01	ARL17A C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 REEP5 TRPT1 ZMIZ2
Forced vital capacity (FVC)	2.63	6	3	6.7	-0.73	1.0e-01	ARFGEF2 ARL17A C17orf81 KANSL1 PIAS4 SPATS2L
BMI	2.61	10	5	11.1	-0.01	9.7e-01	ARFGEF2 C17orf81 C6orf167 FOXO3 PFDN1 PIAS4 PM20D1 PTBP2 REEP5 TRPT1
Trunk fat mass	2.60	10	2	4.4	-0.38	2.8e-01	ARL17A C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 REEP5 RMI1 TRPT1 ZMIZ2
Impedance of arm (left)	2.60	8	3	6.7	0.26	5.4e-01	ARL17A FOXO3 IMMP1L PFDN1 REEP5 RMI1 SH2B3 SPATS2L
Weight	2.59	8	5	11.1	-0.77	2.5e-02	FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 TRPT1 ZMIZ2
Hypertension (Self-reported)	2.58	3	1	2.2	0.00	1.0e+00	C17orf81 PIAS4 SH2B3
Arm fat-free mass (left)	2.58	7	4	8.9	-0.76	4.9e-02	FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Hand grip strength (left)	2.57	1	1	2.2	0.00	1.0e+00	PM20D1
Arm predicted mass (left)	2.55	7	4	8.9	-0.76	4.7e-02	FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Schizophrenia vs Biploar Disorder	2.54	2	0	0.0	0.00	1.0e+00	ARFGEF2 ARHGAP1
Whole body fat mass	2.54	8	3	6.7	-0.39	3.4e-01	ARL17A C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 REEP5 TRPT1
Basal metabolic rate	2.53	7	4	8.9	-0.78	3.9e-02	FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Qualifications: A levels/AS levels or equivalent	2.52	3	0	0.0	0.00	1.0e+00	ARFGEF2 C6orf167 SPATS2L
Arm fat mass (left)	2.52	9	2	4.4	-0.42	2.6e-01	ARL17A C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 REEP5 TRPT1 ZMIZ2
Systolic blood pressure, automated reading	2.48	3	1	2.2	0.00	1.0e+00	ARL17A C17orf81 SH2B3
Comparative body size at age 10	2.48	4	2	4.4	-0.60	4.0e-01	ARL17A CCDC65 KANSL1 PM20D1
Arm predicted mass (right)	2.47	5	4	8.9	-0.72	1.7e-01	FOXO3 PM20D1 REEP5 SH2B3 ZMIZ2
Arm fat-free mass (right)	2.46	6	4	8.9	-0.74	9.2e-02	FOXO3 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Leg fat mass (right)	2.46	7	2	4.4	-0.14	7.6e-01	C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 REEP5 TRPT1
Pulse rate, automated reading	2.46	5	1	2.2	-0.71	1.8e-01	CCDC65 PIAS4 PM20D1 SPATS2L TRPT1
Leg fat mass (left)	2.45	7	2	4.4	-0.13	7.8e-01	C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 REEP5 TRPT1
Whole body fat-free mass	2.43	8	4	8.9	-0.56	1.5e-01	ARFGEF2 FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Whole body water mass	2.43	8	4	8.9	-0.56	1.5e-01	ARFGEF2 FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Leg predicted mass (left)	2.41	7	4	8.9	-0.79	3.3e-02	FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Medication: Blood pressure	2.41	1	1	2.2	0.00	1.0e+00	SH2B3
Arm fat percentage (right)	2.40	8	2	4.4	-0.66	7.3e-02	ARFGEF2 ARL17A C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 TRPT1
Trunk predicted mass	2.40	7	4	8.9	-0.50	2.5e-01	ARFGEF2 FOXO3 KANSL1 PM20D1 REEP5 SH2B3 ZMIZ2
Forced vital capacity (FVC), Best measure	2.40	4	3	6.7	-0.69	3.1e-01	ARFGEF2 ARL17A KANSL1 PIAS4
Leg fat-free mass (left)	2.39	7	4	8.9	-0.79	3.3e-02	FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Trunk fat percentage	2.39	8	2	4.4	-0.56	1.5e-01	ARL17A C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 RMI1 TRPT1
Waist circumference	2.39	6	2	4.4	0.06	9.0e-01	C17orf81 C6orf167 FOXO3 KANSL1 PIAS4 REEP5
Number of self-reported non-cancer illnesses	2.38	1	1	2.2	0.00	1.0e+00	SH2B3
Trunk fat-free mass	2.37	7	4	8.9	-0.50	2.5e-01	ARFGEF2 FOXO3 KANSL1 PM20D1 REEP5 SH2B3 ZMIZ2
Body fat percentage	2.36	8	1	2.2	-0.61	1.1e-01	ARFGEF2 ARL17A C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 TRPT1
Fed-up feelings	2.35	3	1	2.2	0.00	1.0e+00	ARHGAP1 C17orf81 SH2B3
Suffer from 'nerves'	2.35	1	0	0.0	0.00	1.0e+00	ARHGAP1
Frequency of tiredness / lethargy in last 2 weeks	2.34	2	0	0.0	0.00	1.0e+00	ARFGEF2 ARHGAP1
Qualifications: College or University degree	2.34	5	2	4.4	-0.15	8.1e-01	ARFGEF2 C6orf167 FOXO3 PFDN1 SPATS2L
Number of treatments/medications taken	2.33	1	1	2.2	0.00	1.0e+00	SH2B3
Forced expiratory volume in 1-second (FEV1)	2.32	4	3	6.7	-0.76	2.4e-01	ARFGEF2 ARL17A KANSL1 PIAS4
Hand grip strength (right)	2.31	2	1	2.2	0.00	1.0e+00	ARFGEF2 PM20D1
Leg fat-free mass (right)	2.31	7	2	4.4	-0.81	2.8e-02	FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Leg predicted mass (right)	2.31	8	2	4.4	-0.59	1.3e-01	AC009228.1 FOXO3 KANSL1 PM20D1 PTBP2 REEP5 SH2B3 ZMIZ2
Worry (Nagel 2018)	2.27	3	0	0.0	0.00	1.0e+00	ARL17A FOXO3 RMI1
Hip circumference	2.26	7	1	2.2	-0.48	2.8e-01	C17orf81 FOXO3 PIAS4 PTBP2 SH2B3 TRPT1 ZMIZ2
Arm fat percentage (left)	2.26	8	2	4.4	-0.63	9.1e-02	ARFGEF2 ARL17A C6orf167 FOXO3 KANSL1 PIAS4 PTBP2 TRPT1
Medication: Atenolol	2.25	1	1	2.2	0.00	1.0e+00	SH2B3
Frequency of depressed mood in last 2 weeks	2.23	2	0	0.0	0.00	1.0e+00	ARFGEF2 ARHGAP1
Body mass index (BMI)	2.23	6	2	4.4	0.00	9.9e-01	C6orf167 FOXO3 PFDN1 PIAS4 PTBP2 TRPT1
Medication: Blood pressure	2.21	3	1	2.2	0.00	1.0e+00	C17orf81 PIAS4 SH2B3
Taking other prescription medications	2.20	1	1	2.2	0.00	1.0e+00	SH2B3
Hearing difficulty/problems with background noise	2.19	2	0	0.0	0.00	1.0e+00	ARHGAP1 PM20D1
Smoking status: Previous	2.17	1	0	0.0	0.00	1.0e+00	SH2B3
Impedance of whole body	2.17	8	4	8.9	0.05	9.1e-01	ARL17A CCDC65 FOXO3 IMMP1L PFDN1 PM20D1 RMI1 SPATS2L
Comparative height size at age 10	2.15	10	5	11.1	-0.37	2.9e-01	ARFGEF2 ARL17A CCDC3 FOXO3 KANSL1 PIAS4 PM20D1 REEP5 RMI1 SH2B3
Leg fat percentage (right)	2.12	6	1	2.2	-0.39	4.4e-01	ARFGEF2 C6orf167 FOXO3 PIAS4 PTBP2 TRPT1
Illnesses of siblings	2.11	1	0	0.0	0.00	1.0e+00	SH2B3
Depression (Nagel 2018)	2.09	2	0	0.0	0.00	1.0e+00	ARFGEF2 ARHGAP1
Medication: Lisinopril	2.08	1	0	0.0	0.00	1.0e+00	SH2B3
Sitting height	2.07	6	5	11.1	0.20	7.1e-01	AC009228.1 ARFGEF2 CCDC3 FOXO3 PM20D1 REEP5
Standing height	2.06	12	9	20.0	-0.35	2.7e-01	AC009228.1 ARFGEF2 ARL17A CCDC3 FOXO3 KANSL1 PIAS4 PM20D1 REEP5 RMI1 SH2B3 ZMIZ2
Vitamin and mineral supplements	2.05	1	0	0.0	0.00	1.0e+00	SETD2
Leg fat percentage (left)	2.05	5	1	2.2	-0.32	6.0e-01	ARFGEF2 C6orf167 FOXO3 PIAS4 PTBP2
Schizophrenia (2014)	2.04	2	0	0.0	0.00	1.0e+00	ARHGAP1 PTBP2
Lung FVC	2.03	8	4	8.9	-0.39	3.4e-01	ARFGEF2 ARL17A C17orf81 FOXO3 KANSL1 RMI1 SH2B3 SPATS2L
Seen a psychiatrist for nerves, anxiety, tension or depression	2.03	1	0	0.0	0.00	1.0e+00	PM20D1
Age when periods started (menarche)	2.02	2	1	2.2	0.00	1.0e+00	CCDC65 FOXO3
Illnesses of father: Heart disease	2.02	1	0	0.0	0.00	1.0e+00	SH2B3
Bipolar Disorder or Schizophrenia	2.01	2	0	0.0	0.00	1.0e+00	ARHGAP1 SPATS2L
Prostate Cancer	2.01	1	0	0.0	0.00	1.0e+00	PM20D1
Heel T-Score	2.00	8	5	11.1	0.49	2.1e-01	ARHGAP1 C17orf81 CCDC65 IMMP1L PIAS4 REEP5 RMI1 SETD2
Bipolar Disorder (2018)	1.99	1	0	0.0	0.00	1.0e+00	SPATS2L
Height	1.99	14	11	24.4	-0.24	4.1e-01	AC009228.1 ARFGEF2 ARL17A CCDC3 FOXO3 IMMP1L KANSL1 PIAS4 PM20D1 REEP5 RMI1 RP5-921G16.1 SH2B3 ZMIZ2
Neuroticism	1.99	3	0	0.0	0.00	1.0e+00	ARHGAP1 KANSL1 PFDN1
Father's age at death	1.98	1	1	2.2	0.00	1.0e+00	SH2B3
Past tobacco smoking	1.97	1	0	0.0	0.00	1.0e+00	SH2B3
Depressed Affect (Nagel 2018)	1.94	2	0	0.0	0.00	1.0e+00	ARHGAP1 SH2B3
Neuroticism (Nagel 2018)	1.94	3	0	0.0	0.00	1.0e+00	ARHGAP1 ARL17A KANSL1
Blood Platelet Count	1.93	5	5	11.1	-0.03	9.6e-01	ARL17A KANSL1 RMI1 SH2B3 TRPT1
Schizophrenia (2018)	1.89	1	0	0.0	0.00	1.0e+00	ARHGAP1
Coronary Artery Disease (CAD)	1.88	1	0	0.0	0.00	1.0e+00	SH2B3
Alcohol usually taken with meals	1.88	1	0	0.0	0.00	1.0e+00	RMI1
Chronotype (morning person)	1.86	1	1	2.2	0.00	1.0e+00	RMI1
Forced expiratory volume in 1-second (FEV1), Best measure	1.86	4	3	6.7	-0.72	2.8e-01	ARFGEF2 ARL17A KANSL1 PIAS4
Heart attack	1.85	1	0	0.0	0.00	1.0e+00	SH2B3
Handedness (chirality/laterality): Left-handed	1.83	2	0	0.0	0.00	1.0e+00	ARL17A KANSL1
Heart attack/myocardial infarction (self-reported)	1.81	1	0	0.0	0.00	1.0e+00	SH2B3
Medication for cholesterol	1.78	1	1	2.2	0.00	1.0e+00	SH2B3
Medication: Bendroflumethiazide	1.74	1	0	0.0	0.00	1.0e+00	SH2B3
Pulse wave reflection index	1.72	1	0	0.0	0.00	1.0e+00	RMI1
Primary Biliary Cirrhosis	1.71	1	1	2.2	0.00	1.0e+00	SH2B3
Neuroticism score	1.71	1	0	0.0	0.00	1.0e+00	ARHGAP1
LDL Cholesterol	1.64	1	0	0.0	0.00	1.0e+00	SH2B3
Heel bone mineral density (BMD) T-score, automated (right)	1.64	1	1	2.2	0.00	1.0e+00	ARHGAP1
Medication: Allopurinol	1.62	1	0	0.0	0.00	1.0e+00	SH2B3
Illnesses of father: High blood pressure	1.61	1	0	0.0	0.00	1.0e+00	SH2B3
Qualifications: nursing, teaching	1.60	1	0	0.0	0.00	1.0e+00	RMI1
Guilty feelings	1.60	1	0	0.0	0.00	1.0e+00	PFDN1
Number of operations (self-reported)	1.60	1	0	0.0	0.00	1.0e+00	FAM171A1
Tense / 'highly strung'	1.59	1	0	0.0	0.00	1.0e+00	PM20D1
Medication for cholesterol, blood pressure or diabetes	1.59	1	1	2.2	0.00	1.0e+00	SH2B3
Hearing difficulty/problems: Yes	1.58	1	0	0.0	0.00	1.0e+00	C17orf81
Supplements: Vitamin C	1.58	1	0	0.0	0.00	1.0e+00	RMI1
Pain experienced in last month	1.58	1	0	0.0	0.00	1.0e+00	SH2B3
Worry too long after embarrassment	1.54	1	1	2.2	0.00	1.0e+00	PFDN1
Impedance of leg (right)	1.53	4	1	2.2	0.40	6.0e-01	CCDC65 FOXO3 PM20D1 SPATS2L
High blood pressure (siblings)	1.53	1	0	0.0	0.00	1.0e+00	SH2B3
Impedance of leg (left)	1.52	4	0	0.0	0.26	7.4e-01	CCDC65 PFDN1 PM20D1 SPATS2L
Sensitivity / hurt feelings	1.51	1	0	0.0	0.00	1.0e+00	RMI1
Number of live births	1.51	2	0	0.0	0.00	1.0e+00	AC021593.1 TRPT1
Smoking Status	1.50	1	0	0.0	0.00	1.0e+00	KANSL1
Lung FEV1/FVC ratio	1.49	4	2	4.4	-0.71	2.9e-01	ARFGEF2 C17orf81 FOXO3 PM20D1
Heel bone mineral density (BMD) T-score, automated (left)	1.49	1	1	2.2	0.00	1.0e+00	ARHGAP1
Gout (self-reported)	1.49	1	0	0.0	0.00	1.0e+00	SH2B3
Relative age of first facial hair	1.48	1	0	0.0	0.00	1.0e+00	FOXO3
Medication: Aspirin	1.48	1	0	0.0	0.00	1.0e+00	SH2B3
Relative age voice broke	1.46	1	0	0.0	0.00	1.0e+00	FOXO3
Happiness	1.46	1	0	0.0	0.00	1.0e+00	ARFGEF2
Ever smoked	1.42	1	0	0.0	0.00	1.0e+00	SH2B3
Rheumatoid Arthritis	1.41	1	0	0.0	0.00	1.0e+00	SH2B3
Hair/balding pattern: Pattern 4	1.40	1	0	0.0	0.00	1.0e+00	RMI1
Medication: Simvastatin	1.35	1	0	0.0	0.00	1.0e+00	PIAS4
Waist Hip Ratio (WHR)	1.34	3	2	4.4	0.00	1.0e+00	ARL17A KANSL1 SETD2
Type 2 Diabetes (T2D) (2018)	1.33	1	0	0.0	0.00	1.0e+00	SH2B3
Ever depressed for a whole week	1.33	1	0	0.0	0.00	1.0e+00	ARFGEF2
Mouth/teeth dental problems: Mouth ulcers	1.27	1	0	0.0	0.00	1.0e+00	SH2B3
Allergy or Eczema	1.12	1	0	0.0	0.00	1.0e+00	SH2B3
Alcohol intake frequency.	1.10	1	0	0.0	0.00	1.0e+00	AC009228.1
Overall health rating	1.10	1	0	0.0	0.00	1.0e+00	SPATS2L
Breast Cancer	0.86	1	0	0.0	0.00	1.0e+00	C17orf81
Hair Pigment	0.28	5	3	6.7	-0.97	7.7e-03	ARL17A CCDC65 FOXO3 PM20D1 SH2B3
Tanning	0.25	2	0	0.0	0.00	1.0e+00	PFDN1 SH2B3

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Pituitary	6	0.538	2.3
GTEx	Liver	5	0.697	2.2
GTEx	Adrenal Gland	4	0.275	2.1
GTEx	Brain Frontal Cortex BA9	3	0.325	2.1
GTEx	Brain Nucleus accumbens basal ganglia	4	0.462	2.1
GTEx	Brain Putamen basal ganglia	1	0.160	2.1
GTEx	Colon Sigmoid	2	0.137	2.1
GTEx	Esophagus Gastroesophageal Junction	5	0.346	2.1
GTEx	Esophagus Muscularis	9	0.278	2.1
GTEx	Heart Left Ventricle	3	0.196	2.1
GTEx	Muscle Skeletal	8	0.277	2.1
GTEx	Skin Sun Exposed Lower leg	12	0.330	2.1
GTEx	Testis	11	0.349	2.1
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	1	0.197	2.1
GTEx	Adipose Visceral Omentum	4	0.196	2.0
GTEx	Artery Aorta	8	0.269	2.0
GTEx	Artery Coronary	2	0.169	2.0
GTEx	Artery Tibial	9	0.239	2.0
GTEx	Brain Cerebellar Hemisphere	3	0.201	2.0
GTEx	Brain Cerebellum	4	0.202	2.0
GTEx	Brain Cortex	3	0.290	2.0
GTEx	Brain Hippocampus	1	0.191	2.0
GTEx	Breast Mammary Tissue	6	0.304	2.0
GTEx	Colon Transverse	6	0.291	2.0
GTEx	Esophagus Mucosa	9	0.271	2.0
GTEx	Heart Atrial Appendage	3	0.190	2.0
GTEx	Lung	7	0.244	2.0
GTEx	Nerve Tibial	13	0.301	2.0
GTEx	Ovary	4	0.441	2.0
GTEx	Pancreas	5	0.306	2.0
GTEx	Skin Not Sun Exposed Suprapubic	9	0.366	2.0
GTEx	Spleen	3	0.213	2.0
GTEx	Thyroid	10	0.250	2.0
GTEx	Whole Blood	1	0.050	2.0
ROSMAP	Brain Pre-frontal Cortex	5	0.114	2.0
GTEx	Adipose Subcutaneous	9	0.258	1.9
GTEx	Brain Caudate basal ganglia	1	0.109	1.9
GTEx	Brain Hypothalamus	1	0.169	1.9
GTEx	Breast Mammary Tissue (Male)	2	0.168	1.9
GTEx	Breast Mammary Tissue (Female)	2	0.122	1.9
GTEx	Cells EBV-transformed lymphocytes	4	0.281	1.9
GTEx	Cells Transformed fibroblasts	5	0.119	1.9
GTEx	Prostate	4	0.479	1.9
GTEx	Small Intestine Terminal Ileum	0	0.000	1.9
GTEx	Stomach	4	0.275	1.9
GTEx	Vagina	0	0.000	1.9
METSIM	Adipose	7	0.152	1.9
CommonMind	Brain Pre-frontal Cortex	10	0.186	1.9
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	3	0.110	1.9
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	0	0.000	1.9
The Cancer Genome Atlas	Soft Tissue Sarcoma	3	0.281	1.9
The Cancer Genome Atlas	Testicular Germ Cell Tumors	4	0.313	1.9
YFS	Blood	8	0.173	1.8
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	2	0.121	1.8
The Cancer Genome Atlas	Breast Invasive Carcinoma	4	0.091	1.8
The Cancer Genome Atlas	Colon Adenocarcinoma	3	0.145	1.8
The Cancer Genome Atlas	Glioblastoma Multiforme	0	0.000	1.8
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	7	0.171	1.8
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	2	0.098	1.8
The Cancer Genome Atlas	Brain Lower Grade Glioma	5	0.116	1.8
The Cancer Genome Atlas	Lung Adenocarcinoma	3	0.102	1.8
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	3	0.188	1.8
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	2	0.120	1.8
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	2	0.151	1.8
The Cancer Genome Atlas	Prostate Adenocarcinoma	5	0.108	1.8
The Cancer Genome Atlas	Rectum Adenocarcinoma	0	0.000	1.8
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.187	1.8
The Cancer Genome Atlas	Stomach Adenocarcinoma	5	0.297	1.8
The Cancer Genome Atlas	Thyroid Carcinoma	6	0.116	1.8
GTEx	Uterus	1	0.176	1.7
NTR	Blood	1	0.042	1.7
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	2	0.182	1.7
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	2	0.080	1.7
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	1.6